<DOC>
	<DOC>NCT00931125</DOC>
	<brief_summary>This study investigates the hypothesis that ranibizumab injection given into the eye is a safe, efficacious and helping treatment option applied before surgical intervention of the proliferative diabetic retinal eye disorder.</brief_summary>
	<brief_title>Safety and Efficacy of Intravitreal Ranibizumab as a Preoperative Adjunct Treatment Before Vitrectomy Surgery in Proliferative Diabetic Retinopathy (PDR) Compared to Vitrectomy Alone</brief_title>
	<detailed_description>This is a randomized, double blinded , controlled, two-center study assessing the feasibility, efficacy and safety of intravitreal ranibizumab injection applied as a preoperative adjunct treatment before vitrectomy surgery in severe proliferative diabetic retinopathy (PDR). Comparator arm consists of patients receiving standard vitrectomy alone with sham intravitreal injection preoperatively.</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>male or female 18 or older who have signed an informed consent Type I or II diabetes mellitus and severe proliferative retinopathy with tractional retinal detachment, tractionalrhegmatogenous retinal detachment, tractional detachment complicated with vitreous haemorrhage or active severe proliferative retinopathy not responding to previous panretinal laser photocoagulation study eye BCVA must have at least light perception and must not exceed 70 letters using ETDRS at testing distance 4 meters study eye vision decrease must be resulted from severe PDR Active ocular inflammation or infection History of uveitis Uncontrolled glaucoma High myopia Any concurrent intraocular condition in the study eye that in the opinion of the investigator could confound the study results Former treatment with antiangiogenic drugs within 30 days preceding Day 1 in the study eye History of vitrectomy within 60 days preceding Day 1 in the study eye History of intraocular surgery within 30 days preceding Day 1 in the study eye Untreated diabetes mellitus Severe hypertension (systolic pressure higher than 160mmHg) Current use of systemic medications known to be toxic to the retina History of thromboembolic events (incl MI and stroke) within 5 years Major surgery within previous 3 months or planned within the next 28 days Known coagulation abnormalities or current use of anticoagulative medications other than aspirins Known hypersensitivity to ranibizumab or any component of it Women of childbearing potential unless 2 methods of birth control applied Pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Severe proliferative diabetic retinopathy</keyword>
</DOC>